GSK:NYSE
GSK
46,62 $
arrow_upward
+0,20%(+0,095) 1 d.
9. okt., 15:12:44 GMT-4 · USD
search
Visi simboli
| Simbols | Cena | Izmaiņas | % izmaiņu |
|---|
insights_autoNotiek galveno ieskatu ģenerēšana par šādu tēmu: GSK…
Atvērt
46,61 $
Augsta
46,82 $
Zema
46,26 $
Tirgus kapitalizācija
92,91 mljrd.
Vid. apjoms
3,71 milj.
Apjoms
6,48 milj.
Dividende
3,89%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 13. aug.
Cenas/peļņas attiecība
14,94
Augstākā 52 ned.
61,70 $
Zemākā 52 ned.
42,84 $
Peļņa uz vienu akciju
3,12 $
Beta
0,25
Apgrozībā esošās akcijas
2,16 mljrd.
Darbinieku skaits
67 tūkst.
Atvērt
46,61 $
Augsta
46,82 $
Zema
46,26 $
Tirgus kapitalizācija
92,91 mljrd.
Vid. apjoms
3,71 milj.
Apjoms
6,48 milj.
Dividende
3,89%
Ceturkšņa dividendes
0,45 $
Datums, kad tiek pārtraukta dividenžu izmaksa
2026. gada 13. aug.
Cenas/peļņas attiecība
14,94
Augstākā 52 ned.
61,70 $
Zemākā 52 ned.
42,84 $
Peļņa uz vienu akciju
3,12 $
Beta
0,25
Apgrozībā esošās akcijas
2,16 mljrd.
Darbinieku skaits
67 tūkst.
Ziņas un raksti
No tīmekļa avotiem un ziņu partneriem
Traders Union
·
pirms 19 minūtēm
GSK to invest more than $800 million in Pennsylvania biopharma hub
Reuters
·
pirms 23 minūtēm
Pennsylvania says GSK to invest more than $800 million in biopharma hub, create 300 jobs
Seeking Alpha
·
pirms 35 minūtēm
GSK to expand Pennsylvania presence with over $800M investment
The Business Journals
·
pirms 4 stundām
GSK commits $800M to build new Upper Merion facility as pharma investment surges
Profils
GSK plc is a British multinational pharmaceutical and biotechnology company. It was established in 2000 by a merger of Glaxo Wellcome and SmithKline Beecham, which was itself a merger of a number of pharmaceutical companies around the Smith, Kline & French firm. It is headquartered in London, England.
GSK is the tenth-largest pharmaceutical company in the world by earnings, $9.32 billion in 2025 with $42.4 billion in revenues in the same period. As of February 2026 it is the 175th most valuable company in the world and the 12th most valuable pharmaceutical company with a market capitalisation of $122.6 billion. It was also ranked 388th on the 2025 Fortune Global 500.
The company has a primary listing on the London Stock Exchange and is a constituent of the FTSE 100 Index, the eighth largest on the London Stock Exchange behind British pharmaceutical rival AstraZeneca, which occupies the No 1 spot in London at a value of $325 billion, 2.7x more than GSK.
The company developed the first malaria vaccine, RTS, S, which it said in 2014, it would make available for five per cent above cost. Wikipedia
Par “GSK”
ĢenerāldirektorsEmma Walmsley | Emma Walmsley
Darbinieki66,8 tūkst.
Dibināšanas datums2000. gada 27. dec.
Galvenais birojs-
Sektors-
Tīmekļa vietnegsk.com